Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIBOMA capecitabine maintenance after adjuvant chemotherapy in triple-negative operable breast cancer
2005-002838-36Phase 4Completed
- Sponsor
- Coalición Iberoamericana de Investigación en Oncología Mamaria
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Capecitabine maintenance with Observation (2 arms). Primary endpoint: 5-year disease-free survival. Started Nov 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2005-002838-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002838-36.